Posted On: Jun-2026 | Categories : Healthcare
The Home Infusion Therapy Market has evolved beyond a traditional post-acute care category and is increasingly serving as last-mile infrastructure for specialty medicine. As more therapies shift from hospital-based administration to home, ambulatory, and alternate-site settings, market growth is being shaped by the ability to safely manage complex infusion care outside the hospital while maintaining clinical continuity.
According to Strategic Market Research, the Global Home Infusion Therapy Market was valued at USD 39.4 billion in 2025 and is projected to reach USD 66.6 billion by 2032, expanding at a 7.8% CAGR. That growth is not being driven by convenience alone. It is being driven by a larger redesign of specialty care delivery, where hospitals need capacity relief, payers want lower-cost sites of care, patients want fewer facility visits, and drug manufacturers need administration models that can support high-cost biologics, immunotherapies, anti-infectives, parenteral nutrition, immunoglobulins, and chronic specialty therapies.
Home infusion was historically associated primarily with post-discharge intravenous antibiotics and parenteral nutrition for patients unable to meet nutritional needs orally. While these categories remain important, the market has become more clinically and operationally complex. Today, home infusion providers function as clinical logistics networks, coordinating prescription verification, cold-chain management, sterile compounding, pump selection, nursing schedules, prior authorization, patient education, adverse-event monitoring, and physician communication.
This is why the home infusion business cannot be compared with simple home delivery of medicine. The product is not only the drug. The product is the care pathway. A patient receiving IVIG, SCIG, TPN, biologic therapy, anti-infective therapy, enzyme replacement, or hydration support at home needs a coordinated system around them. The therapy must arrive on time, remain stable, be administered correctly, and be monitored safely. If any part of the workflow fails, the site-of-care advantage disappears.
The strongest companies in the market are therefore building around service density rather than drug access alone. Specialty pharmacies, hospital systems, independent home infusion companies, payer-backed platforms, and nursing networks are competing to control the clinical handoff between hospital discharge, specialty prescribing, home administration, and long-term therapy adherence.
The scale of home infusion is no longer limited to a few post-discharge IV antibiotic programs. NHIA’s Home Infusion Drug List now includes more than 350 drugs across 37 therapeutic classes, and roughly 20% of those drugs, or about 70 therapies, account for the most frequent home infusion use. That concentration matters because the market is broad enough to support many therapy categories but still operationally anchored around a smaller group of high-volume, high-need treatments.
The U.S. home infusion ecosystem already serves an estimated 3.2 million patients each year, showing that the model has moved well beyond pilot-stage adoption. The strongest utilization categories remain anti-infectives, immunoglobulins, parenteral nutrition, hydration, pain management, blood factors, and selected biologics. The next layer of growth is coming from specialty drugs that require recurring administration, cold-chain handling, patient monitoring, and payer coordination.
This therapy expansion changes how providers need to think about home infusion. A narrow discharge-focused program may be enough for short-duration antibiotics, but it is not enough for chronic specialty infusion. Immunoglobulin therapy, biologics, parenteral nutrition, and complex specialty drugs require more than delivery capacity. They require clinical protocols, pharmacy documentation, nurse availability, payer coordination, and patient education that can be repeated safely over long treatment cycles.
The primary growth constraint in home infusion is not clinical awareness but operational readiness. Cencora’s Pharmacy Outlook 2026 data indicates that 82% of health systems manage 25% or fewer of their infusion patients at home, while nearly two-thirds do not have a home infusion program in place. As a result, many hospitals continue to shift infusion volume outside their own networks despite payer pressure to move eligible patients away from hospital outpatient departments.
This creates a clear strategic opportunity. Health systems with established home infusion programs report approximately USD 20 million in average annual revenue from these services. For integrated delivery networks, home infusion is evolving beyond discharge support into a revenue-retention, specialty pharmacy, patient-continuity, and site-of-care strategy.
The opportunity is especially important because infusion care often sits close to high-value specialty pharmacy relationships. If a hospital loses the infusion episode, it may also lose visibility into therapy adherence, complications, refill coordination, patient satisfaction, and long-term specialty care engagement. A home infusion program gives hospitals a way to keep patients connected after discharge while creating a more flexible site-of-care model for chronic specialty therapies.
The next phase of home infusion will be shaped not only by current treatment volume but also by the future infusion-therapy pipeline. Cencora notes that more than 60% of drugs currently in development are infusion-delivered therapies. While not all of these therapies will transition to the home setting, the pipeline signals a growing need for more structured infusion strategies across health systems, specialty pharmacies, and payer networks.
As biologics, immunotherapies, rare-disease drugs, and specialty therapies expand, the market will need more flexible administration models than hospital infusion suites alone can provide. Infusion rooms will remain essential for high-risk and complex therapies, but they cannot absorb every future specialty treatment if drug pipelines continue shifting toward infused or injectable modalities.
The operational focus is shifting from infusion feasibility to the safest, most cost-effective, and most patient-centered site of care. For some therapies, hospital-based infusion will remain necessary. For others, ambulatory infusion suites will be appropriate, while an increasing share of lower-risk or clinically stable patients may be managed through home infusion.
The rise of home infusion is closely tied to specialty pharmacy. Specialty pharmacies already manage complex drug access, benefits verification, prior authorization, cold-chain shipping, adherence support, and manufacturer program coordination. When infusion capability is added, they become the operational center of a decentralized specialty-care model.
This is why home infusion providers are increasingly judged by their ability to integrate pharmacy and nursing. A specialty pharmacy can dispense the drug, but infusion therapy requires trained clinicians, vascular access expertise, pump management, emergency preparedness, and patient education. The providers that can combine both layers are better positioned to manage chronic, high-cost therapies.
This also explains why hospitals are paying more attention to the category. If health systems allow all infusion migration to happen outside their network, they risk losing patient relationships, specialty pharmacy revenue, and control over care quality. But building a home infusion program is not easy. It requires nursing coverage, pharmacy infrastructure, contracting, accreditation, electronic documentation, supply-chain reliability, and 24/7 response capacity.
For hospitals, the opportunity extends beyond revenue generation to care continuity. Hospital-owned or hospital-partnered home infusion models can help reduce inpatient length of stay, optimize infusion-chair capacity, improve discharge planning, and maintain ongoing engagement with specialty-care patients.
The primary operational constraint in home infusion is not drug availability but nursing capacity. Infusion nurses represent the frontline infrastructure of the market, supporting patient training, venous access assessment, therapy administration or supervision, reaction monitoring, outcome documentation, and early identification of complications.
This makes labor availability one of the most important growth constraints. A hospital outpatient infusion center can serve multiple patients in one location. Home infusion requires clinicians to travel, manage scheduling variation, work across home environments, and often coordinate with caregivers. This makes the economics different. The market can scale only if providers improve routing, documentation, digital support, patient self-administration training, and risk stratification.
That is why the future of home infusion will depend heavily on hybrid models. Not every infusion requires a nurse at every visit. Some patients need full nurse administration. Others can be trained for self-administration with periodic monitoring. Some therapies can shift to subcutaneous delivery. Others require pump-based administration with remote support. The more precisely providers can match patient risk, therapy complexity, and nursing intensity, the more scalable the market becomes.
Technology is expanding the range of therapies that can be safely managed outside the hospital. Ambulatory infusion pumps, elastomeric pumps, syringe pumps, smart pump platforms, remote monitoring tools, digital check-ins, and electronic care coordination are making home infusion more standardized and clinically controlled. The objective is not to replace clinical judgment, but to reduce variability in care delivery.
A major technology trend is the growing adoption of wearable on-body delivery systems for large-volume subcutaneous administration. These platforms are designed to reduce reliance on prolonged intravenous infusion sessions by enabling controlled subcutaneous drug delivery in home-based or lower-acuity care settings. Enable Injections’ enFuse platform, for example, supports large-volume subcutaneous administration and received FDA approval as part of the EMPAVELI Injector for adults with paroxysmal nocturnal hemoglobinuria.
This matters because many biologics and specialty drugs are difficult to move home if they require long chair time, complex IV handling, or frequent facility monitoring. If drug-device combinations can reduce administration burden, they can change the commercial model. A therapy that once required hours in an infusion suite may eventually become suitable for self-administration, nurse-supported home care, or hybrid monitoring.
The broader device opportunity is not limited to pumps. It includes digital adherence tools, patient training platforms, electronic nursing documentation, adverse-event reporting systems, cold-chain tracking, remote monitoring, and integration with electronic medical records. The home infusion provider of the future will look less like a delivery company and more like a distributed clinical operations platform.
Oncology is one of the most discussed frontiers for home infusion, but it also requires the most careful framing. Some cancer-related therapies can be delivered at home safely for selected patients. Others should remain in controlled clinical settings because of reaction risk, toxicity, hazardous handling, stability concerns, or need for immediate medical intervention.
Penn Medicine’s Cancer Care at Home program shows what is possible when home infusion is supported by multidisciplinary infrastructure. The model includes physician selection, oncology-trained nurses, pharmacy coordination, safety protocols, and careful therapy choice. That is the important lesson: home oncology infusion is not a blanket site-of-care shift. It is a drug-by-drug, patient-by-patient, protocol-by-protocol decision.
This creates a realistic market opportunity. The growth area may not be broad chemotherapy migration. It may be supportive oncology care, hydration, antiemetics, selected injectables, hormone therapies, low-risk infusions, and carefully chosen systemic therapies under specialized oversight. Providers that overstate the speed of oncology migration may face clinical resistance. Providers that build safety-first oncology pathways may gain trust.
Reimbursement remains one of the most important constraints in the market. CMS describes the Medicare home infusion therapy benefit as covering professional services for certain drugs and biologicals administered intravenously or subcutaneously through a pump that qualifies as durable medical equipment. That includes professional services, nursing services, patient training, education, remote monitoring, and other monitoring services tied to the plan of care.
The challenge is that home infusion reimbursement is split across drugs, supplies, equipment, pharmacy services, nursing services, and payer-specific benefit structures. This fragmentation creates documentation burden and denial risk. Providers need strong authorization teams, clean coding, accurate nursing documentation, and payer-specific workflows.
CMS’s 2024 HIT monitoring data, highlighted by NHIA, shows that only 203 suppliers participated in the Medicare home infusion therapy benefit out of nearly 1,500 eligible infusion pharmacies, and just seven suppliers accounted for more than half of all HIT visits. That concentration points to a major access gap. Coverage may exist on paper, but provider participation remains limited when reimbursement does not fully match the operational reality of care delivery.
This is why home infusion cannot scale through clinical demand alone. Providers need reimbursement pathways that recognize pharmacy coordination, nursing, equipment, supplies, patient training, monitoring, documentation, and 24/7 clinical support. If reimbursement does not reflect the full care model, providers may avoid certain therapies or geographies even when patients are clinically appropriate for home-based treatment.
The economic case for home infusion remains powerful when the right patients and therapies are selected. Published evidence has shown savings of USD 1,928 to USD 2,974 per treatment course when home infusion is compared with medical-setting infusion. That cost advantage explains why payers continue to expand site-of-care policies and why hospital outpatient infusion departments face increasing pressure to reserve chairs for patients who truly need facility-level monitoring.
For commercial payers, the value proposition is centered on site-of-care optimization. Hospital outpatient departments often carry higher administration costs than alternative care settings. When therapy can be delivered safely at home, health systems may reduce facility charges, avoid unnecessary hospital utilization, and improve patient convenience. However, cost savings depend on nursing efficiency, drug stability, patient selection, caregiver support, travel distance, prior authorization requirements, and complete clinical documentation.
This is why payer strategies are becoming more sophisticated. The goal is no longer simply to push every infusion out of the hospital. The goal is to identify which therapies, patient profiles, and geographies can safely support lower-cost care without creating new clinical risks or service delays.
Biosimilars are becoming an important site-of-care catalyst. As biosimilar competition expands across immunology, oncology support, inflammatory disease, and other biologic categories, payers and specialty pharmacies have more incentive to rethink where these therapies are administered. Lower product costs can make home and alternate-site models more financially workable, especially for chronic therapies.
For home infusion providers, biosimilars create both opportunity and operational complexity. They may increase payer willingness to authorize lower-cost therapy pathways, but they also require education, formulary management, physician acceptance, substitution rules, and patient communication. Providers that can help prescribers and payers navigate biosimilar adoption will become more valuable partners.
This is especially relevant in autoimmune and inflammatory diseases, where long-term biologic treatment can create high cumulative costs. When biosimilars, specialty pharmacy management, and alternate-site infusion are combined, the market can reduce both drug and facility-cost pressure.
The home infusion market is consolidating because scale matters. National and regional providers need payer contracts, pharmacy infrastructure, nurse coverage, supply-chain reliability, data systems, and broad therapy capabilities. Smaller providers can still compete in specialized niches, but they face pressure from larger platforms that can negotiate with payers, serve multiple geographies, and standardize clinical operations.
Independent home infusion platforms are competing on nursing quality, specialty focus, payer relationships, and geographic reach. Health-system-owned or health-system-affiliated infusion programs are using the model to protect patient continuity and create new revenue opportunities while supporting hospital capacity management. Specialty pharmacy-led infusion companies are bringing drug access, payer authorization, manufacturer relationships, and chronic therapy management into the home infusion workflow. Device-enabled care companies are entering as the infrastructure layer, using pumps, wearable injectors, remote monitoring, and digital care coordination to make home-based therapy safer and more scalable.
The leading model is unlikely to be defined by a single company type. It is more likely to depend on coordinated partnerships. A health system may retain the patient relationship, a specialty pharmacy may manage therapy access, a nursing network may provide administration, and a device platform may support delivery and monitoring. Home infusion is therefore evolving into a partnership-driven market, as no single stakeholder can fully address the last-mile care delivery challenge alone.
The next phase of the Home Infusion Therapy Market will be defined by last-mile execution. More drugs are eligible, more patients prefer home-based care, more payers are pushing site-of-care optimization, and more hospitals are evaluating whether they should build, partner, or outsource. But the market will not be won by drug access alone.
Biologics redesigned for subcutaneous or wearable delivery will expand the addressable home-care pool. Nursing workforce strategies will determine how fast providers can scale. Payer site-of-care policies will decide how much volume shifts from hospital outpatient departments to home and alternate sites. Oncology-at-home models will grow only where drug selection, patient risk assessment, oncology-trained nursing, and safety protocols are strong enough. Hospital systems that treat home infusion as a strategic service line rather than an outsourced discharge tool will be better positioned to capture specialty-care revenue and improve patient retention.
The winners will be the organizations that can coordinate pharmacy, nursing, pumps, patient training, payer approval, remote monitoring, adverse-event response, and documentation at scale. In that sense, home infusion is becoming less like a traditional service line and more like a distributed specialty-care operating system.
Home infusion therapy is becoming one of the clearest examples of healthcare moving from buildings to networks. The hospital will remain essential for acute, unstable, and high-risk patients. But for eligible patients on appropriate therapies, the home is becoming a clinically managed treatment site.
The market’s next winners will not be the providers that simply deliver medication to the patient’s door. They will be the organizations that can manage the last mile of specialty care: pharmacy accuracy, nurse availability, device reliability, payer approval, patient training, clinical monitoring, and emergency readiness.
That is the real transformation in the Home Infusion Therapy Market. The future is not just infusion at home. It is specialty care redesigned around the patient, supported by pharmacy, nursing, technology, and payer logic working as one operating system.